Yahoo Finance Pre-Market Analysis on STSI, IPXL, PCYC, and UTHR
StockCall.com Provides Stock Research on Star Scientific Inc., Impax Laboratories Inc., Pharmacyclics Inc., and United Therapeutics Corp.
New York City, New York -- (May 21, 2013)
A recent report from IMS showed that U.S. spending on medicines fell in 2012. The drop in medicines spending highlights the increasing competition drug manufacturers are facing from generic companies. The “patent cliff”, which refers to the expiration of patents on several blockbuster drugs over the next few years, is likely to result in further competition from generic drug makers. Another challenge facing drug manufacturers is President Obama’s healthcare reform, the Affordable Care Act (ACA). Shares of drug manufacturers ended on a mixed note on Monday as the broad market fluctuated between gains and losses. Among the major movers were Star Scientific Inc. (NASDAQ:STSI - News), Impax Laboratories Inc. (NASDAQ:IPXL - News), Pharmacyclics Inc. (NASDAQ:PCYC - News) and United Therapeutics Corporation (NASDAQ:UTHR - News) which mainly remained range bound.StockCall has posted free technicalresearch on STSI, IPXL, PCYC, and UTHR which can be downloaded upon sign up at
Star Scientific Inc.’s stock is down 47.17 percent on a YTD basis, despite its 9.38 percent gain in the previous session. The stock closed at $1.40 after trading in the range of $1.27 and $1.40. The stock shows a neutral streak and may touch $1.53 level. Its second resistance level is at $1.84. It traded 1.18 million shares during yesterday’s session. The company lost 57.83 percent of its value in the past 52 weeks and traded in the range of $1.15 and $5.05 during the same time period. It is currently trading above its short-term moving average price of $1.32.Sign up and read the complimentary report on STSI at
www.StockCall.com/STSI052113.pdf
Impax Laboratories Inc. traded in the range of $14.41 and $27.25 in its latest trading session. Its volume stood at 662,818 shares, down from its average daily volume of 1.01 million. Impax Laboratories Inc. closed the session at $18.43, up 0.05 percent. The stock is currently trading below its short-term moving average price of $18.44. In the coming sessions, Impax is expected to go as high as $19.62, while its first support level is at $19.99. The stock trades at beta of 0.33 and thus has very low volatility. It has declined 7.9 percent on a YTD basis, while its 52 weeks decline stands at 12.11 percent.The free report on IPXL can be downloaded by signing up now at
www.StockCall.com/IPXL052113.pdf
Pharmacyclics Inc. is currently trading in a neutral territory and consequently the stock may see some pullback in the coming sessions. It closed its Monday’s session at $81.86, down 3.57 percent. The stock may touch $80.06 level in the coming days. Upon breaching this level, the stock’s next support price is at $76.17. Pharmacyclics’ stock has low volatility with its beta at 0.87. So far in 2013, the stock appreciated 41.97 percent. Its 52 weeks gain stands at 186.22 percent. The stock has traded in the range of $27.30 and $95.85 during the said time period. It is currently trading above its short-term moving average price of $80.59 and long-term moving average price of $80.72.Free report on PCYC can be accessed by registering at
www.StockCall.com/PCYC052113.pdf
United Therapeutics Corporation trimmed its 52 weeks gain by closing 1.53 percent lower. The stock ended Monday’s session at $68.11, while its highest price point for the session stood at $69.26. It traded 382,936 shares, down from its average daily volume of 801,697. The company’s shares traded in the range of $41.55 and $69.26 in the past 52 weeks. UTHR commands market capitalization of $3.38 billion, and it reported its latest EPS at $5.63. Its stock grew more than 63.57 percent in the past 52 weeks. The stock is mildly volatile with its beta at 0.93.Register withStockCall and download the research on UTHR for free at
www.StockCall.com/UTHR052113.pdf
About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at
Contact Person:
William T. Knight
Email: info@stockcall.com
Contact Number: (646) 396-9857 (9:00 am EST – 01:30 pm EST)
